Stock listing
LS Exchange:A2JRNS Liquidia Corporation Aktie
German listing (LS Exchange) of Liquidia Corporation · home listing NASDAQ:LQDA
Follow Liquidia Corporation into a list and get an email when it puts out news.
Home listing price · NASDAQ:LQDA
$54.43 USD -1.97 (-3.5%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:LQDA
- Day range
- $53.98 – $57.21 USDNov 20, 2026
- Volume
- 1.69M sharesNov 20, 2026
- Market cap
- $4.90B USDAt the close on Nov 20, 2026 · price × 90.11M shares outstanding
- 52-week range
- $22.31 – $93.61 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $140.0M USDMedian day 1.87M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:LQDA · Home | $54.43 USD | -1.97 (-3.5%) | 1,690,880 | $56.49 | $57.21 | $53.98 | $56.40 | Close on Nov 20, 2026 |
| Frankfurt:LT4 | €51.08 EUR | -0.30 (-0.6%) | — | €51.08 | €51.08 | €51.08 | €51.38 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:LQDA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $54.43 | -1.97 | -3.5% | $56.49 | $57.21 | $53.98 | 1,690,880 | |
| $56.40 | -0.33 | -0.6% | $57.27 | $58.82 | $55.80 | 1,217,969 | |
| $56.73 | +0.36 | +0.6% | $56.49 | $57.21 | $54.80 | 1,804,679 | |
| $56.37 | -1.04 | -1.8% | $57.00 | $58.08 | $55.85 | 1,766,109 | |
| $57.41 | -0.71 | -1.2% | $58.37 | $59.49 | $57.00 | 1,870,344 | |
| $58.12 | +2.91 | +5.3% | $55.00 | $58.74 | $54.01 | 2,809,779 | |
| $55.21 | +3.81 | +7.4% | $54.00 | $56.79 | $52.76 | 3,777,378 | |
| $51.40 | +3.53 | +7.4% | $48.73 | $51.69 | $46.24 | 2,847,088 | |
| $47.87 | +3.47 | +7.8% | $45.60 | $48.24 | $45.09 | 2,157,757 | |
| $44.40 | -0.09 | -0.2% | $44.60 | $45.69 | $44.23 | 1,291,366 | |
| $44.49 | -2.89 | -6.1% | $47.38 | $47.46 | $44.39 | 1,949,560 | |
| $47.38 | +5.18 | +12.3% | $43.32 | $51.11 | $43.24 | 4,808,598 | |
| $42.20 | +0.35 | +0.8% | $41.69 | $43.37 | $41.58 | 2,182,208 | |
| $41.85 | -3.21 | -7.1% | $45.71 | $45.71 | $41.66 | 2,582,625 | |
| $45.06 | +0.07 | +0.2% | $44.99 | $46.29 | $44.24 | 2,090,619 | |
| $44.99 | -0.73 | -1.6% | $46.23 | $47.20 | $44.41 | 2,609,056 | |
| $45.72 | +0.28 | +0.6% | $45.40 | $47.18 | $45.00 | 2,235,901 | |
| $45.44 | +1.70 | +3.9% | $43.88 | $46.36 | $43.70 | 3,145,646 | |
| $43.74 | +1.09 | +2.6% | $42.77 | $45.72 | $42.12 | 4,113,322 | |
| $42.65 | +2.96 | +7.5% | $39.86 | $42.83 | $38.69 | 3,800,500 | |
| $39.69 | +0.83 | +2.1% | $38.75 | $40.08 | $38.22 | 3,532,000 | |
| $38.86 | +2.51 | +6.9% | $36.65 | $39.20 | $36.51 | 3,878,500 | |
| $36.35 | +2.22 | +6.5% | $33.90 | $36.93 | $33.65 | 3,993,600 | |
| $34.13 | -0.22 | -0.6% | $34.42 | $36.82 | $33.76 | 3,026,100 | |
| $34.35 | -0.43 | -1.2% | $34.78 | $34.90 | $33.33 | 4,548,200 | |
| $34.78 | +0.84 | +2.5% | $34.93 | $35.80 | $32.20 | 7,220,200 | |
| $33.94 | +7.13 | +26.6% | $35.70 | $38.64 | $33.12 | 21,143,400 | |
| $26.81 | -0.86 | -3.1% | $27.04 | $27.40 | $26.13 | 7,653,300 | |
| $27.67 | +0.29 | +1.1% | $29.27 | $30.86 | $27.28 | 4,413,100 | |
| $27.38 | -0.64 | -2.3% | $27.06 | $28.53 | $26.67 | 3,617,000 | |
| $28.02 | +1.34 | +5.0% | $26.34 | $29.35 | $26.34 | 5,259,500 | |
| $26.68 | +0.77 | +3.0% | $25.55 | $27.33 | $24.59 | 6,982,200 | |
| $25.91 | -1.73 | -6.3% | $27.95 | $28.30 | $25.76 | 5,307,000 | |
| $27.64 | -1.00 | -3.5% | $28.07 | $28.48 | $25.92 | 7,755,100 | |
| $28.64 | +0.65 | +2.3% | $26.69 | $29.18 | $26.31 | 8,394,700 | |
| $27.99 | -2.27 | -7.5% | $23.96 | $28.10 | $22.31 | 21,573,300 | |
| $30.26 | -40.43 | -57.2% | $70.54 | $71.93 | $29.86 | 22,953,200 | |
| $70.69 | -2.98 | -4.0% | $72.49 | $73.15 | $68.74 | 1,532,900 | |
| $73.67 | +5.24 | +7.7% | $68.05 | $74.74 | $67.66 | 1,206,300 | |
| $68.43 | -2.52 | -3.6% | $71.60 | $71.81 | $67.55 | 967,300 | |
| $70.95 | +3.46 | +5.1% | $67.04 | $71.41 | $66.75 | 1,026,100 | |
| $67.49 | -1.15 | -1.7% | $68.60 | $68.60 | $67.10 | 765,900 | |
| $68.64 | +2.21 | +3.3% | $66.59 | $68.76 | $66.00 | 1,139,000 | |
| $66.43 | -0.45 | -0.7% | $67.18 | $67.41 | $65.74 | 1,010,200 | |
| $66.88 | -1.51 | -2.2% | $68.08 | $68.72 | $66.57 | 3,895,700 | |
| $68.39 | -0.06 | -0.1% | $69.51 | $70.81 | $67.41 | 1,082,300 | |
| $68.45 | +2.73 | +4.2% | $65.67 | $69.87 | $65.34 | 1,296,400 | |
| $65.72 | +0.41 | +0.6% | $65.31 | $65.93 | $62.86 | 1,372,100 | |
| $65.31 | -1.43 | -2.1% | $66.79 | $66.90 | $65.13 | 1,074,400 | |
| $66.74 | -1.11 | -1.6% | $68.66 | $69.94 | $66.68 | 778,500 | |
| $67.85 | -1.27 | -1.8% | $67.87 | $68.35 | $66.62 | 955,000 | |
| $69.12 | +1.44 | +2.1% | $67.39 | $69.39 | $67.35 | 997,300 | |
| $67.68 | -0.98 | -1.4% | $68.00 | $69.21 | $67.07 | 1,329,000 | |
| $68.66 | +0.03 | 0.0% | $67.91 | $69.47 | $67.40 | 900,200 | |
| $68.63 | -1.05 | -1.5% | $69.27 | $70.75 | $68.15 | 931,700 | |
| $69.68 | +2.77 | +4.1% | $67.40 | $70.13 | $66.73 | 1,282,600 | |
| $66.91 | -1.26 | -1.8% | $67.70 | $69.00 | $66.10 | 1,410,000 | |
| $68.17 | +0.48 | +0.7% | $67.10 | $68.27 | $66.10 | 1,054,400 | |
| $67.69 | -2.25 | -3.2% | $69.99 | $70.31 | $67.57 | 926,300 | |
| $69.94 | -1.42 | -2.0% | $71.01 | $71.70 | $69.51 | 548,700 | |
| $71.36 | +0.87 | +1.2% | $70.14 | $72.96 | $70.00 | 846,000 | |
| $70.49 | +0.22 | +0.3% | $71.50 | $73.07 | $70.10 | 931,000 | |
| $70.27 | +1.65 | +2.4% | $67.77 | $71.11 | $67.25 | 1,291,300 | |
| $68.62 | -2.43 | -3.4% | $70.91 | $71.13 | $68.05 | 1,698,900 | |
| $71.05 | -4.28 | -5.7% | $73.55 | $74.53 | $70.85 | 1,583,500 |
- Ticker
- LS Exchange:A2JRNS
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- LS Exchange
- Currency
- EUR
What changed lately
Latest news release · Nov 10, 2026
Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference
Latest earnings call · Nov 10, 2026
Liquidia (NASDAQ:LQDA) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 10, 2026
Q3 2026 Earnings Presentation
Earnings · 10 slides
Latest news
Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference
Nov 10, 2026
Closed $51.40 (+7.4%) on Nov 10, 2026
Liquidia Corporation Reports Third Quarter 2026 Financial Results
Nov 10, 2026
Closed $51.40 (+7.4%) on Nov 10, 2026
Liquidia Corporation to Report Third Quarter 2026 Financial Results on November 10, 2026
Nov 3, 2026
Closed $42.20 (+0.8%) on Nov 3, 2026
Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH
Oct 13, 2026
Closed $33.94 (+26.6%) on Oct 14, 2026
Liquidia Provides Update on Hatch-Waxman Litigation Tied to ‘327 Patent
Sep 30, 2026
Closed $30.26 (-57.2%) on Sep 30, 2026
FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis
Sep 3, 2026
Closed $68.63 (-1.5%) on Sep 3, 2026
Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress
Sep 2, 2026
Closed $69.68 (+4.1%) on Sep 2, 2026
Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference
Sep 1, 2026
Closed $66.91 (-1.8%) on Sep 1, 2026
Liquidia Corporation Reports Second Quarter 2026 Financial Results
Aug 12, 2026
Closed $78.79 (-10.5%) on Aug 12, 2026
Liquidia Corporation to Report Second Quarter 2026 Financial Results on August 12, 2026
Jul 29, 2026
Closed $86.82 (0.0%) on Jul 29, 2026
Liquidia Corporation on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 21 in the last 12 months · 196 in all · newest Nov 10, 2026 · oldest 2019
- Calls
- 23 calls with a replay · 23 with a transcript · latest Nov 10, 2026
- Decks
- 10 decks · latest Nov 10, 2026
Where Liquidia Corporation is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:LQDA · Home listing | NASDAQ | United States | USD |
| gettex:LT4 | gettex | Germany | EUR |
| Tradegate:LT4 | Tradegate | Germany | EUR |
| LS Exchange:A2JRNS · This page | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2JRNS | Lang & Schwarz | Germany | EUR |
| BOATS:LQDA | BOATS | United States | USD |
| Frankfurt:LT4 | Frankfurt | Germany | EUR |
| Stuttgart:LT4 | Stuttgart | Germany | EUR |
| Dusseldorf:LT4 | Dusseldorf | Germany | EUR |
| Munich:LT4 | Munich | Germany | EUR |
| Hamburg:LT4 | Hamburg | Germany | EUR |
| Hanover:LT4 | Hanover | Germany | EUR |
| Xetra:LT4 | Xetra | Germany | EUR |
Valuation
EV/sales 7.5× against a median of 5.7×: 6th lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $4.68B USD
- P/E
- Loss
- EV/sales
- 7.5×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- 92.7%
- Operating margin
- −15.6%
- Net margin
- −15.2%
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 0.84
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Liquidia Corporation · NASDAQ:LQDA | US$4.90B | US$4.68B | n/a | 7.5× | n/a | n/a | −15.2% | n/a | 0.84 |
| Belite Bio, Inc. · NASDAQ:BLTE | US$5.13B | US$5.13B | n/a | n/a | n/a | 6.6× | n/a | 0.0× | 1.34 |
| SK Biopharmaceuticals Co., Ltd. · KRX:326030 | US$5.05B | US$4.77B | 16.9× | 7.5× | 20.1× | 6.7× | 46.6% | 0.0× | n/a |
| Veradermics, Incorporated · NYSE:MANE | US$5.04B | US$4.25B | n/a | n/a | n/a | 6.3× | n/a | 0.0× | 1.13 |
| Erasca, Inc. · NASDAQ:ERAS | US$4.78B | US$4.18B | n/a | n/a | n/a | 5.2× | n/a | 0.1× | 1.51 |
| Dianthus Therapeutics, Inc. · NASDAQ:DNTH | US$4.76B | US$3.92B | n/a | 1,444× | n/a | 3.8× | n/a | 0.0× | 0.90 |
| PTC Therapeutics, Inc. · NASDAQ:PTCT | US$4.71B | US$3.12B | n/a | 2.7× | n/a | n/a | −9.2% | n/a | 0.88 |
| Cogent Biosciences, Inc. · NASDAQ:COGT | US$4.65B | US$4.08B | n/a | n/a | n/a | 9.0× | n/a | 0.4× | 1.30 |
| Kiniksa Pharmaceuticals International, plc · NASDAQ:KNSA | US$4.53B | US$3.97B | 41.4× | 4.2× | 29.9× | 6.4× | 11.6% | 0.0× | 0.57 |
| Travere Therapeutics, Inc. · NASDAQ:TVTX | US$4.51B | US$4.21B | n/a | 6.5× | n/a | 200× | −18.7% | 0.0× | 1.31 |
| Ionis Pharmaceuticals, Inc. · NASDAQ:IONS | US$4.43B | US$4.70B | n/a | 4.9× | n/a | 11.3× | −56.9% | 5.5× | 0.40 |
| Median of the others | US$4.74B | US$4.19B | 29.2× | 5.7× | 25.0× | 6.6× | −9.2% | 0.0× | 1.13 |
Forecasts
5 strong buy · 1 buy · 2 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 66.13 USD · Analysts' mean
- EPS, year to Dec 2026
- 0.075 · 2 analysts
- Revenue, year to Dec 2026
- 759.6M · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Roger Jeffs | Chief Executive Officer |
| Patrick Wallace | Director, Corporate Communications |
| Jason Adair | Chief Business Officer |
Board
| Director | Role |
|---|---|
| Stephen Bloch | Chairman |
| Arthur Kirsch | Board Member |
| Damian deGoa | Board Member |
| David Johnson | Board Member |
| Joanna Horobin | Board Member |
| Katie Rielly-Gauvin | Board Member |
| Paul Manning | Board Member |
| Raman Singh | Board Member |
| Roger Jeffs | Chief Executive Officer |
Events
Calls
| Call | When | Status |
|---|---|---|
| Liquidia (NASDAQ:LQDA) Q3 2026 Earnings Call | Tue, Nov 10, 2026 · 8:30 AM ET | Replay |
| Liquidia (NASDAQ:LQDA) Q2 2026 Earnings Call | Wed, Aug 12, 2026 · 8:30 AM ET | Replay |
| Liquidia (NASDAQ:LQDA) Q1 2026 Earnings Call | Mon, May 11, 2026 · 8:30 AM ET | Replay |
| Liquidia (NASDAQ:LQDA) Q4 2025 Earnings Call | Thu, Mar 05, 2026 · 8:30 AM ET | Replay |
| Liquidia (NASDAQ:LQDA) Q3 2025 Earnings Call | Mon, Nov 03, 2025 · 8:30 AM ET | Replay |
| Liquidia (NASDAQ:LQDA) Q2 2025 Earnings Call | Tue, Aug 12, 2025 · 8:30 AM ET | Replay |
| Liquidia (NASDAQ:LQDA) Q1 2025 Earnings Call | Thu, May 08, 2025 · 8:30 AM ET | Replay |
| Liquidia (NASDAQ:LQDA) Q4 2024 Earnings Call | Wed, Mar 19, 2025 · 8:30 AM ET | Replay |
| Liquidia (NASDAQ:LQDA) Q3 2024 Earnings Call | Wed, Nov 13, 2024 · 8:30 AM ET | Replay |
| Liquidia (NASDAQ:LQDA) Q2 2024 Earnings Call | Wed, Aug 07, 2024 · 8:30 AM ET | Replay |
All 23 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · Before open | +7.4% |
| Q2 2026 | Aug 12, 2026 · Before open | −10.5% |
| Q1 2026 | May 11, 2026 · Before open | +25.6% |
| Q4 2025 | Mar 12, 2026 | −4.9% |
| Q3 2025 | Nov 3, 2025 · Before open | +3.5% |
| Q2 2025 | Aug 12, 2025 · Before open | +13.7% |
| Q1 2025 | May 8, 2025 · Before open | −1.2% |
| Q4 2024 | Mar 19, 2025 | +4.8% |
| Q3 2024 | Nov 13, 2024 · Before open | −3.4% |
| Q2 2024 | Aug 7, 2024 · Before open | −3.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 13, 2024 · After close | −1.5% |
| Q4 2023 | Mar 13, 2024 · Before open | +5.4% |
| Q3 2023 | Nov 7, 2023 · Before open | +3.7% |
| Q2 2023 | Aug 10, 2023 · Before open | +3.1% |
| Q1 2023 | May 4, 2023 · After close | +1.1% |
| Q4 2022 | Mar 16, 2023 · Before open | +15.3% |
| Q3 2022 | Nov 8, 2022 · After close | +0.4% |
| Q2 2022 | Aug 11, 2022 · After close | +27.9% |
| Q1 2022 | May 12, 2022 · After close | +13.9% |
| Q4 2021 | Mar 17, 2022 · Before open | +5.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 10 slides | Nov 10, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 12 slides | Aug 12, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 10 slides | May 11, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 8 slides | Mar 5, 2026 |
| J.P. Morgan Healthcare Conference 2026 | Conference | 21 slides | Jan 14, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 9 slides | Nov 3, 2025 |
| Investor Day (October 2025) | Investor day | 62 slides | Oct 28, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 9 slides | Aug 12, 2025 |
| Corporate Update (May 2025) | Corporate update | 12 slides | May 27, 2025 |
| J.P. Morgan Healthcare Conference 2025 | Conference | 22 slides | Jan 15, 2025 |
Financings
| Raise | Date |
|---|---|
| Royalty financing (sixth amendment to HCRx agreement) Tranche closed: US$50M raised Buyers: HealthCare Royalty (HCRx) (funded an additional $50.0 million) Use of proceeds: Accelerate YUTREPIA launch, advance clinical pipeline, and expand manufacturing including build-out of newly leased facility | Jun 23, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 158.3M | 14.0M | 17.5M | 15.9M | 12.9M | 739.6K | 8.07M | 2.71M | 7.26M | 13.2M |
| Cost of revenue | 13.2M | 5.88M | 2.89M | 2.86M | 3.02M | 237.7K | 807.2K | 121.4K | 319.8K | 918.8K |
| Gross profit | 145.1M | 8.12M | 14.6M | 13.1M | 9.83M | 501.9K | 7.26M | 2.59M | 6.94M | 12.3M |
| Research and development | 39.3M | 47.8M | 43.2M | 19.4M | 20.5M | 32.2M | 40.5M | 28.7M | 24.8M | 23.3M |
| Selling, general and administrative | 157.2M | 81.6M | 44.7M | 32.4M | 23.1M | 27.4M | 13.6M | 8.75M | 10.2M | 4.84M |
| Operating income | -51.4M | -121.3M | -73.4M | -38.8M | -33.8M | -59.1M | -46.8M | -34.9M | -28.0M | -15.9M |
| Depreciation and amortization | 1.53M | 2.20M | 2.18M | 3.65M | 5.61M | 3.13M | 2.57M | 1.54M | 931.9K | 651.6K |
| EBITDA | -49.8M | -119.1M | -71.2M | -35.1M | -28.2M | -56.0M | -44.3M | -33.3M | -27.1M | -15.2M |
| Interest expense | 24.2M | 14.7M | 6.27M | 2.34M | 762.0K | 858.0K | 1.37M | 19.0M | 13.0M | 85.9K |
| Income before tax | -68.9M | -130.4M | -78.5M | -41.0M | -34.6M | -59.8M | -47.6M | -53.1M | -29.2M | -15.9M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 720.4K | 13.0M | 14.9K |
| Net income | -68.9M | -128.3M | -78.5M | -41.0M | -34.6M | -59.8M | -47.6M | -53.1M | -29.2M | -15.9M |
| Earnings per share, basic | -0.80 | -1.63 | -1.21 | -0.67 | -0.70 | -1.76 | -2.57 | -7.42 | -3.40 | -3.13 |
| Earnings per share, diluted | -0.80 | -1.63 | -1.21 | -0.67 | -0.70 | -1.76 | -2.57 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 190.7M | 176.5M | 83.7M | 93.3M | 57.5M | 65.3M | 55.8M | 39.5M | 3.42M | 1.44M |
| Receivables | 54.1M | 2.72M | 4.06M | 5.02M | 2.99M | 0 | 272.6K | 1.62M | 1.24M | |
| Inventory | 23.8M | 241.0K | 1 | 1 | 1 | 1 | ||||
| Current assets | 273.4M | 185.1M | 89.9M | 99.8M | 61.3M | 66.1M | 56.4M | 40.0M | 5.48M | 3.15M |
| Property, plant and equipment | 11.8M | 8.30M | 4.48M | 4.15M | 5.02M | 6.81M | 9.25M | 8.13M | 8.24M | 4.35M |
| Goodwill | 3.90M | 3.90M | 3.90M | 3.90M | 3.90M | 3.90M | 0 | |||
| Total assets | 327.9M | 230.3M | 118.3M | 129.2M | 93.7M | 99.5M | 68.8M | 49.4M | 14.8M | 8.49M |
| Accounts payable | 3.68M | 4.69M | 1.40M | 2.20M | 1.07M | 3.73M | 3.50M | 3.24M | 4.42M | 2.41M |
| Current liabilities | 135.8M | 41.8M | 18.6M | 8.80M | 7.33M | 11.7M | 16.9M | 8.25M | 30.5M | 12.1M |
| Long-term debt | 132.9M | 97.4M | 43.4M | 19.9M | 10.4M | 10.3M | 10.3M | 11.6M | 5.56M | 5.22M |
| Total debt | 197.9M | 122.4M | 49.5M | 19.9M | 10.4M | 10.3M | 15.9M | 12.8M | 23.5M | 8.68M |
| Total liabilities | 283.2M | 150.9M | 71.0M | 38.8M | 28.5M | 28.4M | 33.9M | 30.7M | 48.5M | 26.7M |
| Shareholders' equity | 44.7M | 79.4M | 47.3M | 90.4M | 65.3M | 71.1M | 34.9M | 18.7M | -33.7M | -18.2M |
| Shares outstanding | 87.2M | 84.7M | 68.6M | 64.5M | 52.3M | 43.3M | 28.2M | 7.16M | 8.59M | 5.09M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -35.7M | -93.4M | -41.6M | -28.6M | -34.0M | -54.1M | -48.3M | -31.8M | -24.3M | -13.9M |
| Capital spending | -4.34M | -4.95M | -1.29M | -592.0K | -107.0K | -752.1K | -1.85M | -870.9K | -2.54M | -2.89M |
| Free cash flow | -40.0M | -98.4M | -42.9M | -29.2M | -34.1M | -54.9M | -50.1M | -32.7M | -26.8M | -16.8M |
| Cash from investing | -6.34M | -8.44M | -11.3M | -587.0K | -107.0K | 247.9K | -1.85M | -870.9K | -2.54M | -2.89M |
| Cash from financing | 59.7M | 194.7M | 43.2M | 65.0M | 26.3M | 63.4M | 66.4M | 68.8M | 28.8M | 6.11M |
| Share buybacks | 62.4M | 72.8M | 96.7K | 445.5K | ||||||
| Change in cash | 17.7M | 92.8M | -9.60M | 35.8M | -7.82M | 9.52M | 16.3M | 36.1M | 1.98M | -10.7M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 19, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 18, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 18, 2026 | Management or board change | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Oct 13, 2026 | Material contract | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 30, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 15, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 14, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 11, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 3, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 25, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 21, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 19, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 19, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 17, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 4, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 8, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 17, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 10, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 8, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 8, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 21, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 20, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 15, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 14, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 11, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | May 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 11, 2026 | Results | SEC |
| 144 · Notice of proposed sale | May 8, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 7, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 29, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 24, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 21, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 17, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 16, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 14, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 14, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 9, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 30, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 27, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 26, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 13, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 9, 2026 | Other filings | SEC |
| S-3ASR · Registration statement | Mar 5, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 5, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 5, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 5, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 5, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 9, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 13, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 9, 2026 | Current report | SEC |
| 4 · Change in ownership | Dec 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 18, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 7, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 5, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 3, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 3, 2025 | Results | SEC |
| 8-K · Current report | Oct 30, 2025 | Material contract | SEC |
| 4 · Change in ownership | Oct 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Sep 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 15, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 5, 2025 | Insider trade | SEC |
This page holds 200 of 710 filings. Open Filings
Cap table
Built by 6ix from Liquidia Corporation’s releases · as of Oct 28, 2026
- Common shares
- 90,106,442
- Fully diluted
- 90,106,442
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 90,106,442 | Oct 28, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 28, 2026 | 90,106,442 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Paul B. Manning Other companies: Candel Therapeutics, Inc. (Chair of the Board · Since at least Jul 26, 2021); Verrica Pharmaceuticals Inc. (Chairman · Since at least Jun 14, 2018); Taysha Gene Therapies, Inc. (Director · Sep 23, 2020 – Oct 31, 2022 · Past); Dova Pharmaceuticals Inc (Director · Jun 28, 2017 – Nov 12, 2019 · Past); AveXis Inc (Director · Feb 10, 2016 – Feb 10, 2016 · Past); Perrigo Company plc (EVP & General Manager, PBM · Jun 9, 2010 – Jun 9, 2010 · Past) | Board Member · Since at least Nov 18, 2020 |
| Roger Jeffs Other companies: Axsome Therapeutics, Inc. (DIRECTOR · Since at least Nov 19, 2015); Sio Gene Therapies Inc (Director · Feb 8, 2018 – Apr 15, 2019 · Past); Albireo Pharma Inc (Director · Sep 27, 2017 – Jun 24, 2021 · Past); Dova Pharmaceuticals Inc (Director · Jun 28, 2017 – Nov 12, 2019 · Past); Sangamo Therapeutics, Inc. (Director · Jun 26, 2017 – Sep 7, 2018 · Past); United Therapeutics Corporation (President & Co-CEO, Director · Jan 5, 2006 – Mar 15, 2016 · Past) | Chief Executive Officer · Since at least Nov 18, 2020 |
| Arthur Kirsch Other companies: Evommune, Inc. (Audit · Since at least Nov 5, 2025); Atea Pharmaceuticals, Inc. (Director · Since at least Feb 20, 2025); Kadmon Holdings Inc (Director · May 15, 2019 – Nov 9, 2021 · Past); Aralez Pharmaceuticals Inc (Director · May 12, 2016 – Dec 8, 2017 · Past) | Board Member · Since at least Mar 24, 2021 |
| Michael Kaseta Other companies: Heron Therapeutics, Inc. (Director · Since at least Nov 4, 2024); Alimera Sciences Inc (Director · Mar 24, 2023 – Sep 16, 2024 · Past); Aralez Pharmaceuticals Inc (Chief Financial Officer · Nov 30, 2017 – Mar 15, 2018 · Past) | CFO and COO · Since at least Nov 30, 2020 |
| Stephen Bloch Other companies: Marinus Pharmaceuticals Inc (Director · Jul 31, 2014 – Sep 24, 2015 · Past); Amicus Therapeutics Inc (Director · May 30, 2007 – Feb 11, 2009 · Past) | Chairman · Since at least Mar 24, 2021 |
| Joanna Horobin Other companies: Kymera Therapeutics, Inc. (Director · Jun 7, 2024 – Jun 7, 2024 · Past) | Director · Since at least Jun 20, 2024 |
| Damian deGoa | Director · Since at least Jun 17, 2025 |
| Dana Boyle | Chief Accounting Officer · Since at least Jul 1, 2025 |
| David Johnson | Director · Since at least May 19, 2026 |
| Harold Alterson | See Remarks · Since at least Nov 16, 2026 |
All 22 people
| Person | Seat |
|---|---|
| Jason Adair | Chief Business Officer · Since at least Jul 21, 2021 |
| Katherine Rielly-Gauvin | Director · Since at least Jun 16, 2026 |
| Katie Rielly-Gauvin | Board Member · Since at least Aug 21, 2026 |
| Patrick Wallace | Director, Corporate Communications · Since at least Jan 27, 2026 |
| Rajeev Saggar | Chief Medical Officer · Since at least Jul 18, 2022 |
| Raman Singh | Board Member · Since at least Mar 24, 2021 |
| Robert A Lippe | Chief Operations Officer · Nov 30, 2023 – Nov 30, 2023 · Past |
| Russell Schundler | See Remarks · Since at least Mar 29, 2021 |
| Sanjeev Khindri | Chief Development Officer · Since at least Jan 1, 2026 |
| Sarah Krepp | Chief Human Resource Officer · Since at least Jul 1, 2025 |
| Scott Moomaw | Chief Commercial Officer · Since at least Nov 18, 2020 |
| Tushar Shah | CMO and Head of R&D · Jan 19, 2021 – Jan 16, 2022 · Past |
Log in to ask 6ix AI your own questions about Liquidia Corporation.